UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
Urogen Pharma (URGN) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $1.22 per share a year ago.
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Urogen Pharma (URGN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.18 per share a year ago.

Why Shares of UroGen Pharma Jumped Friday

01:41pm, Friday, 28'th Jul 2023
UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next year.
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen has an approved drug and a platform. However, there's not much growth in revenue.
Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bladder cancers due to its ability to allow molecules to reside in the target space for an ex
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director-Investor Relations Liz Barrett - President & Chi
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter
Urogen Pharma Ltd (NASDAQ:URGN ) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director M
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and CEO Mark Schoenberg
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE